Latest Auditing News

Argo Investments reported a stable $260.2 million profit for FY2026 with fully franked dividends rising to 38.5 cents per share. The LIC maintains a conservative investment approach, low costs, and strong governance as it marks 80 years.

Winton Land has named Michael Stiassny as its new independent chair, stepping into a leadership role during a period of significant board and executive change. The company is actively recruiting additional independent directors and senior executives to stabilise governance and operations.

Corporate Travel Management (ASX:CTD) posted a $17.7 million profit for FY26, reversing a $348.5 million loss the previous year, driven by stronger earnings in ANZ and Europe and progress on UK customer settlements.

Energy One Limited (ASX:EOL) reported a robust FY2026 with a 17% increase in recurring revenue and a 51% jump in net profit before tax, while preparing for a transformative acquisition of Gas Management Services Limited to deepen its European market presence.

Fonterra expects its FY26 underlying earnings to reach the upper limit of its 60-70 cents per share guidance, signaling steady performance and underpinning a strong dividend outlook.

Underwood Capital Limited (ASX:UWC) reported a net profit after tax of $0.193 million for FY2026, with net tangible asset backing per share inching up to 9.46 cents. Despite portfolio improvements and active share buybacks, the stock continues to trade below its net asset value.

Australian Unity Limited (ASX:AYU) posted a statutory loss of $155.2 million for FY2026, reflecting regulatory headwinds, transformation costs, and sector disruptions, while advancing its climate risk management and strategic portfolio adjustments.

Prestal Holdings Limited posted a 30% drop in sales to $10.3 million and a $3.6 million net loss for FY26, while exiting its core Hampers With Bite business in a strategic pivot.

Collins Foods posted record FY26 revenue and underlying profit, exited Taco Bell to focus on KFC growth, and outlined ambitious expansion plans in Germany and Australia.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.